Johnson & Johnson (JNJ)

JNJ on New York Consolidated

102.95USD
28 Aug 2014
Price Change (% chg)

$-0.27 (-0.26%)
Prev Close
$103.22
Open
$102.90
Day's High
$103.19
Day's Low
$102.71
Volume
3,485,694
Avg. Vol
6,194,304
52-wk High
$106.74
52-wk Low
$85.50

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies located in 60 countries, including the United States, which sell products... (more)

Overall

Beta: 0.59
Market Cap (Mil.): $291,110.09
Shares Outstanding (Mil.): 2,820.29
Dividend: 0.70
Yield (%): 2.71

Financials

  JNJ Industry Sector
P/E (TTM): 19.08 32.39 33.40
EPS (TTM): 5.41 -- --
ROI: 14.72 17.97 17.27
ROE: 21.06 18.61 18.02
Search Stocks

Johnson & Johnson to seek buyer for medical device maker unit: WSJ

- Johnson & Johnson plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter.

8:30pm EDT

Johnson & Johnson to seek buyer for medical device maker unit -WSJ

Aug 28 - Johnson & Johnson plans to seek a buyer for its medical device maker business, Cordis Corp, The Wall Street Journal reported citing people familiar with the matter.

8:27pm EDT

FDA says Johnson & Johnson recalls some jaw implants

- Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.

9:14am EDT

UPDATE 1-FDA says Johnson & Johnson recalls some jaw implants

Aug 28 - Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw, following more than a dozen cases of injury.

9:11am EDT

FDA says Johnson & Johnson recalls some jaw implants

Aug 28 - Johnson & Johnson is recalling some lots of its implant used to correct defects of the jaw following more than a dozen cases of injury.

8:17am EDT

Healthcare: A remedy for long-term investors

CHICAGO - (The opinions expressed here are those of the author, a columnist for Reuters.)

04 Aug 2014

COLUMN-Healthcare: A remedy for long-term investors

(The opinions expressed here are those of the author, a columnist for Reuters.)

04 Aug 2014

J&J seeks return of device seen as possibly raising cancer risk

- Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

30 Jul 2014

J&J seeks return of device seen as possibly raising cancer risk

July 30 - Johnson & Johnson said on Wednesday it plans to ask doctors to return its power morcellators, a controversial surgical device that may inadvertently spread cancer in women being treated for uterine growths called fibroids.

30 Jul 2014

Europe backs new leukemia drugs from J&J and Gilead

LONDON - Two new leukemia drugs from Johnson & Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months.

25 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Wright Reports
$75.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks